The Long Read: Innovation, Access & Affordability in the USA
A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to…
Tagged with Kyowa Kirin
Rare Disease Strategies in the Booming US Market
Rare disease – defined in the US as a disease with a maximum patient population of 200,000 – is perhaps the most salient issue at the nexus of…
Essential Tips for Taking on a New Role in Pharma During a…
COVID-19 has necessitated enormous shifts in the way we live, work, and communicate with each other. Nowhere is this more apparent professionally than…
3 US Pharma Mid-Cap Execs to Know
The US heads for three leading international mid-cap innovators – Japanese firms Eisai and Kyowa Kirin and Danish outfit Lundbeck – explain their…
Gary Zieziula – President & Region Head North America,…
Gary Zieziula, president & region head North America for Kyowa Kirin, a specialty care-focused Japan-based global pharma company, highlights the…
The UAE: A Gathering Force
Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most…
The UAE: Early Adopters of Cutting-Edge Medical Technology
In some respects, is it perhaps the medtech sector that has most to be excited about in the UAE’s domestic market, given the country’s unrelenting…
Embracing Innovation: The UAE as an Initial Product Launch…
The UAE’s distinctive willingness to embrace innovation and the ‘can-do’ spirit of authorities marks the country out as worthy of attention as…
Myriam Hakim – General Manager GCC, Kyowa Kirin
Myriam Hakim, the recently appointed GM for Japanese specialty pharma firm Kyowa Kirin’s UAE affiliate, discusses the strategic significance of the…
